Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 11, 2013, Pages 1770-1781

  Flynn, Jacqueline K ^a,b   Dore, Gregory J ^c   Hellard, Margaret ^a   Yeung, Barbara ^c   Rawlinson, William D ^e   White, Peter A ^d   Kaldor, John M ^c   Lloyd, Andrew R ^d   Ffrench, Rosemary A ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Acute hepatitis C; Immune response; Injecting drug users; PEG IFN ; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 2; PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SCREENING; TH1 CELL; VIRAL CLEARANCE; VIRUS INFECTION;

ACUTE HEPATITIS C; IMMUNE RESPONSE; INJECTING DRUG USERS; PEG-IFN-Α; T CELLS;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CELLS, CULTURED; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; TH1 CELLS;

EID: 84897605463     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12265     Document Type: Article

References (47)

1. Santantonio T, Massimo F, Sinisi E etal. Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 2005; 42: 329-333.
2. Dore GJ, Hellard M, Matthews G etal. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123-135.
3. Wiegand J, Boescher W, Buggish P etal. 24 weeks of monotherapy with pegylated interferon alfa-2b in patients with acute hepatitis C infection. Hepatology 2003; 38: 277A.
4. Broers B, Helbling B, Francois A etal. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J. Hepatol. 2005; 42: 323-328.
5. Gerlach JT, Diepolder HM, Zachoval R etal. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88.
6. Kamal SM, Ismail A, Graham CS etal. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-1731.
7. McGovern BH, Nagami EH, Birch CE etal. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J. Infect. Dis. 2009; 200: 877-881.
8. Gruner NH, Gerlach TJ, Jung MC etal. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 2000; 181: 1528-1536.
9. Gerlach JT, Diepolder HM, Jung M-C etal. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
10. Kamal SM, Fouly AE, Kamel RR etal. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-638.
11. + memory T cells. J. Virol. 2008; 82: 10017-10031.
12. Wiegand J, Jackel E, Cornberg M etal. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.
13. Rahman F, Heller T, Sobao Y etal. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40: 87-97.
14. Wiegand J, Cornberg M, Aslan N etal. Fate and function of hepatitis-C-virus-specific T cells during peginterferon-α2b therapy for acute hepatitis C. Antivir. Ther. 2007; 12: 303-316.
15. Lauer GM, Lucas M, Timm J etal. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J. Virol. 2005; 79: 12979-12988.
16. Schulze zur Wiesch J, Ciuffreda D, Lewis-Ximenez L etal. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J. Exp. Med. 2012; 209: 61-75.
17. Abdel-Hakeem MS, Bédard N, Badr G etal. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J. Virol. 2010; 84: 10429-10435.
18. Lechner F, Wong DKH, Dunbar PR etal. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 2000; 191: 1499-1512.
19. Wedemeyer H, He X-S, Nascimbeni M etal. Impaired effector function of hepatitis c virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 2002; 169: 3447-3458.
20. Radziewicz H, Ibegbu CC, Fernandez ML etal. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 2007; 81: 2545-2553.
21. Flynn JK, Dore GJ, Hellard M etal. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J. Viral Hepat. 2011; 18: 549-561.
22. Grebely J, Matthews GV, Hellard M etal. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J. Hepatol. 2011; 55: 76-85.
23. Morishima C, Morgan T, Everhart J etal. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006; 44: 360-367.
24. Grebely J, Petoumenos K, Hellard M etal. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
25. Flynn JK, Dore GJ, Matthews G etal. Impaired HCV-specific IFN-γ responses in individuals with HIV who acquire HCV infection correlate with levels of CD4 cells. J. Infect. Dis. 2012; 206: 1568-1576.
26. Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001; 194: 1395-1406.
27. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell responses in hepatitis C infection. J. Clin. Virol. 2005; 32: 75-85.
28. Wherry JE, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 2004; 78: 5535-5545.
29. Francavilla V, Accapezzato D, De Salvo M etal. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur. J. Immunol. 2004; 34: 427-437.
30. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001; 19: 65-91.
31. Lancaster T, Sanders E, Christie JML, Brooks C, Green S, Rosenburg WMC. Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J. Viral Hepat. 2002; 9: 18-28.
32. Bacosi M, De Angelis A, Ursitti A etal. Association of circulating CD8+ lymphocytes to a spontaneous and interferon-a induced clearance of HCV. Hepatol. Res. 2002; 23: 163-166.
33. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur. J. Immunol. 2000; 30: 2479-2487.
34. Bonavita MS, Franco A, Paroli M etal. Normalization of depressed natural killer activity after interferon-a therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int. J. Tissue React. 1993; 15: 11-16.
35. Khakoo SI, Thio CL, Martin MP etal., eds. Synergistic influence of HLA and inhibitory KIR on spontaneous resolution of hepatitis C virus infection. 8th Annual Meeting of the Society for Natural Immunity; 2004, Noordwijkerhout, the Netherlands.
36. Kaplan DE, Ikeda F, Li Y etal. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J. Hepatol. 2008; 48: 903-913.
37. Blackburn SD, Wherry JE. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007; 15: 143-146.
38. Opal SM, Huber CE. The role of interleukin-10 in critical illness. Curr. Opin. Infect. Dis. 2000; 13: 221-226.
39. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006; 12: 1301-1309.
40. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001; 19: 683-765.
41. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J. Immunol. 2008; 180: 5771-5777.
42. Bengsch B, Spangenberg HC, Kersting N etal. Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J. Virol. 2007; 81: 945-953.
43. Golden-Mason L, Burton JR Jr, Castelblanco N etal. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006; 44: 1098-1109.
44. + T cells associated with reversible immune dysfunction. J. Virol. 2007; 81: 9249-9258.
45. Urbani S, Amadei B, Tola D etal. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 2006; 80: 11398-11403.
46. Radziewicz H, Ibegbu CC, Hon H etal. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during chronic phase of infection. J. Virol. 2008; 82: 9808-9822.
47. Veerapu NS, Raghuraman S, Liang J, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulate cellular immune responses. Gastroenterology 2011; 140: 676-685.